Our study is unable to distinguish NLRC5 downregulation of which cells in the tumor – infiltrating immune cells or melanoma cells themselves – has a greater contribution to the progression of melanoma and the response of immunotherapy, further work is needed to clarify this question. The gene discussed is NLRC5; the disease is melanoma.